Riluzol-Hormosan

Quick links

Choose a section

Quick links to important sections

Advertisements

Riluzol-Hormosan

Advertisements
Advertisements

Method of action: Other Nervous System Drugs

Advertisements

Overview of Riluzol-Hormosan

Property Description
Active ingredient Riluzole
Form Oral tablet, Oral suspension
Pharmacological class Glutamate Inhibitor, Neuroprotective agent
General purpose To provide neuroprotection
Origin Synthetic (Small Molecule)

What Type of Medicine is Riluzol-Hormosan?

Riluzol-Hormosan is a prescription-only medication, a specific trade name for the active ingredient Riluzole (INN), manufactured by Hormosan Pharma GmbH. Riluzole is chemically classified as a benzothiazole derivative and is fundamentally defined as a Neuroprotective agent and an Excitatory Amino Acid Antagonist. This synthetic small molecule is designed to influence chemical signaling in the nervous system. Riluzole's structure is documented as 2-amino 6-(trifluoromethoxy)benzothiazole. This classification places it within a specialized group of pharmaceuticals intended to modulate underlying neurological processes rather than focusing on general symptom relief.


Understanding the Form and Composition of Riluzole

The active substance Riluzole is strictly intended for oral administration, with Riluzol-Hormosan typically available as an oral tablet. This drug is a single-ingredient product, containing only Riluzole as the pharmaceutically active component, combined with necessary excipients. This single focus ensures targeted delivery of the neuroprotective compound. The general purpose of this therapy is to help preserve neurological function in adults facing progressive neurodegenerative conditions.


What is the General Purpose of Riluzole?

The general purpose of Riluzole is to provide a neuroprotective effect by mitigating the destructive process of over-excitation in nerve cells. It primarily functions as a Glutamate Inhibitor, helping to regulate the excessive release and activity of the chemical messenger glutamate in the central nervous system. By limiting this glutamatergic neurotransmission, the medication offers the general benefit of helping to shield vulnerable neurons from continuous over-stimulation and damage, thereby contributing to the stability of neurological function.

Regulatory References

  1. MedlinePlus Drug Information
Advertisements

What side effects are possible with Riluzol-Hormosan?

Possible Side Effects and Safety Information

The official safety profile for Riluzol-Hormosan, containing Riluzole, classifies adverse reactions based on their documented frequency in regulatory sources, affecting several system-organ classes including the hepatobiliary, gastrointestinal, and nervous systems.

Frequency-Classified Adverse Reactions

Classification Examples of Officially Documented Effects
Very Common (ge 1/10) Asthenia, Nausea, Elevated Liver Enzymes (ALT)
Common (ge 1/100 to < 1/10) Headache, Dizziness, Somnolence, Diarrhoea
Uncommon (ge 1/1,000 to < 1/100) Neutropenia, Interstitial Lung Disease (ILD), Anaphylactoid Reactions

Serious Adverse Reactions and Safety Constraints

The prescribing information documents several serious adverse reactions, notably Hepatic Injury, Severe Neutropenia, Pancreatitis, and Interstitial Lung Disease. These risks structure the mandated safety monitoring required during use.

Elevations in liver enzymes are a key safety focus, with the highest increases most frequently observed within the first three months of treatment initiation. Consequently, Riluzole is contraindicated in patients with pre-existing severe hepatic impairment.

Official documents also detail precautions for specific populations, stating that use is not recommended in patients with impaired renal function due to limited study data, and caution is advised regarding the risk of dizziness or somnolence which may affect the ability to perform skilled tasks.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The information in this section is based on official government regulatory documents detailing the potential signs and required actions in the event of an overdose with Riluzol-Hormosan (Riluzole).

Classification Official Regulatory Statement
Documented Overdose Manifestations Symptoms have included neurological and psychiatric symptoms, such as confusion, drowsiness, tremors, and involuntary movements.
Severe Outcomes Life-threatening outcomes observed in isolated cases include acute toxic encephalopathy, stupor, and coma. The serious systemic complication of Methaemoglobinaemia has also been documented, which may be signaled by bluish coloring of the lips, fingernails, or palms.
Management Strategy No specific antidote are available. Treatment, in all cases of overdose, is stated to be symptomatic and supportive.

Required Emergency Actions:

Immediate medical help is required for any suspected overdose. Immediately call emergency services if the affected person has collapsed, had a seizure, has trouble breathing, or can't be awakened.


The documented profile emphasizes the risk of severe neurological and systemic compromise, including oxygen-carrying complications. This risk dictates the need for mandatory, immediate emergency medical attention, as officially documented in prescribing information. The management approach is officially limited to supportive measures, given the confirmed absence of a specific neutralizing agent.

Advertisements

Therapeutic Uses of Riluzol-Hormosan

Riluzol-Hormosan is indicated for the treatment of Amyotrophic Lateral Sclerosis (ALS), a condition marked by increased physiological stress. It is relevant in contexts involving heightened systemic burden. The medication is used to support patients diagnosed with this condition.

Quick Fact: Supports in managing Physical Discomfort


Support for Symptomatic Discomfort

Riluzol-Hormosan is applied in clinical settings that involve acute or disruptive symptom patterns, helping to ease the overall burden of symptoms related to physical discomfort and systemic imbalance. The medication supports the patient during difficult episodes and contributes to easing the overall symptom load.

“Applied across domains where additional symptomatic support is needed.”


Management of Fluctuating Symptoms

The medication is commonly used across conditions involving episodic or fluctuating manifestations, relevant for managing symptoms that interfere with daily comfort. Its use assists with maintaining functional stability and is relevant when supportive symptom management is appropriate to help patients cope more steadily with symptom fluctuations. It is applied in addressing symptom clusters related to heightened physiological activity and functional stress.


Assistance During Phases of Heightened Tension

Riluzol-Hormosan is applied during phases where the patient experiences heightened discomfort. It is relevant in situations requiring temporary assistance in symptom stabilization. This provides supportive relief that helps maintain a sense of stability when symptoms become more noticeable and supports general well-being during symptomatic phases.

Regulatory References

  1. European Medicines Agency (EMA) public assessment report
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Riluzol-Hormosan — official regulatory information

Eligibility Scope

Category Regulatory Status
Populations for whom use is allowed Adults and older people with a diagnosis of Amyotrophic Lateral Sclerosis (ALS).
Populations for whom use is not recommended Paediatric population (children and adolescents) and patients with impaired renal function (due to insufficient study data).
Populations for whom use is contraindicated Patients with a history of severe hypersensitivity reactions to riluzole or any component; patients with hepatic disease or baseline transaminases greater than 3 times the Upper Limit of Normal (ULN).

Age-related eligibility rules: Use is specifically indicated for the adult population, including older adults. Use is not recommended in the paediatric population.

Condition-specific eligibility rules: The medicine is contraindicated if baseline serum transaminases are above 3 imes ULN. Discontinuation is required if a patient's transaminase levels reach 5 times the ULN.

Pregnancy and lactation eligibility status (if explicitly documented): Use is contraindicated during both pregnancy and breastfeeding.


Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents):

  • Contraindicated: Applies to severe hypersensitivity, established hepatic disease, pregnancy, and lactation.
  • Not Recommended: Applies to the paediatric population and individuals with impaired renal function.

Official eligibility statements:

  • The medicine is contraindicated in patients with hepatic disease or baseline transaminases greater than 3 imes ULN.
  • Use is not recommended in the paediatric population and in patients with impaired renal function.

Connection to the overall eligibility profile: Official regulatory documents strictly define the eligible population for Riluzol-Hormosan as adults with ALS. These documents establish mandatory exclusions, explicitly contraindicating the medicine for individuals with specific baseline liver impairments, severe hypersensitivity reactions, or those who are pregnant or breastfeeding.

Advertisements

What should I know about interactions with other medicines?

Riluzole is metabolized primarily by the CYP1A2 enzyme pathway, which is the main basis for its most significant drug interactions. The clearance of riluzole is affected by co-administration with other medicines that either slow down or speed up this metabolic process.

Potential Interactions

Category of Interacting Product Mechanism and Potential Effect
Strong or Moderate CYP1A2 Inhibitors Increases riluzole concentrations in the blood, which may raise the risk of riluzole-associated adverse reactions. Examples include ciprofloxacin, enoxacin, fluvoxamine, mexiletine, and zileuton.
Strong or Moderate CYP1A2 Inducers Decreases riluzole concentrations in the blood, potentially resulting in reduced drug efficacy.
Hepatotoxic Drugs Concomitant use with other drugs known to cause liver injury (e.g., allopurinol, methyldopa, sulfasalazine) may increase the overall risk of hepatotoxicity; patients should be monitored closely.

Food and Timing

Food interaction is also a documented factor. Taking riluzole with a meal, particularly a high-fat meal, significantly reduces the absorption of the drug, decreasing its maximum concentration ( C max) and overall exposure (AUC). To ensure proper absorption, the drug should be administered at least one hour before or two hours after a meal.

Advertisements

Mechanism of Action

Riluzole acts primarily within the central nervous system to modulate glutamatergic neurotransmission. Its molecular targets include voltage-dependent sodium channels, which it interacts with as an inhibitor. This functional blockade on presynaptic terminals restricts the inward sodium flux necessary for action potential propagation, leading to reduced neuronal excitability and a consequent inhibition of glutamate release into the synaptic cleft.

Downstream, riluzole influences the clearance of glutamate by acting as an inducer of the cystine/glutamate transporter (xCT), thereby accelerating the uptake of the neurotransmitter from the extracellular space. This dual action—reducing presynaptic release and enhancing synaptic clearance—results in a net system-level reduction in excitatory neurotransmitter signaling.

Intracellularly, riluzole has also been observed to interfere with signaling pathways, including an inhibitory effect on the catalytic activity of protein kinase CK1delta and the modulation of NMDA and kainate receptors through noncompetitive or indirect mechanisms. These actions collectively stabilize neuronal cell function by modulating ion homeostasis and attenuating signal transduction cascades that follow excessive excitatory input.

Advertisements

Dosage and Administration Information

How Riluzol-Hormosan is Used: General Administration Guidelines

Riluzol-Hormosan is used according to a standardized protocol. Adherence to these precise instructions regarding dose, frequency, and conditions of intake is essential for proper administration.


Dosing and Administration Schedule

Guideline Instruction
Route of Administration Oral use (by mouth) as a tablet or oral suspension. The suspension form may also be given via PEG-tubes.
Standard Daily Dose 100 mg total, split into two 50 mg doses.
Dosing Frequency Twice daily (BID), with doses taken approximately 12 hours apart.
Timing Relative to Meals Must be taken on an empty stomach. Administration should be at least one hour before or two hours after a meal to prevent reduced absorption.

Procedural and Population-Specific Rules

Treatment initiation must be handled by specialist physicians experienced in the management of motor neuron diseases.

Instructions for use include:

  • Preparation: If using the oral suspension, the container should be gently shaken for at least 30 seconds before measuring the dose.
  • Missed Dose: If a dose is missed, that dose should be skipped. The patient should resume the medication schedule by taking the next dose at the regular time, without doubling up.
  • Older Adults: Patients in this age group use the same recommended dose of 100 mg/day.
  • Pediatric Use: Use of Riluzole is not recommended in pediatric patients due to the absence of sufficient data regarding safety and efficacy in that population.
Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Riluzol-Hormosan


Evidence for use in Amyotrophic Lateral Sclerosis (ALS) / Motor Neuron Disease (MND)

The foundational evidence for Riluzol was gathered in major clinical trials, primarily two large, short-to-intermediate term Randomized Controlled Trials (RCTs) that compared outcomes of patients receiving the medicine against those receiving an inactive placebo. The main focus of this research examined regulatory outcomes related to time-to-event such as survival and time until the need for breathing support (tracheostomy). Researchers also monitored outcomes related to daily functioning or activity level using standardized scales to see how symptoms evolved over the study period.

Studies reported patterns related to measured differences in survival time in the original RCTs described a small difference compared to the placebo groups. Further research, including large-scale observational studies using real-world data, explored longer time frames. Research examining the functional scales explores whether differences exist, and the pivotal studies did not establish a clear difference in these measurements between the observed groups.


Long-term Follow-up and Real-World Evidence

The question of long-term outcomes and long-term data collection was evaluated in follow-up research. Because the initial RCTs had follow-up durations that were limited to about 18 months, an understanding of the long-term course of the disease and the role of the medicine was studied for many years afterward through observational settings evaluating daily-life functioning and large patient registries. The evidence derived from these settings, however, is considered less certain than RCT data because, unlike trials, the observational studies lacked randomization and the populations were not strictly controlled. Certainty remains low regarding the precise magnitude of the observed survival data over many years.


Research Gaps: What is Still Being Investigated

Overall, the research base includes a foundation of two large, gold-standard RCTs which contribute to a High level of evidence supporting the study of survival time. However, several areas of research remain insufficient and are still under active exploration. Comparative evidence is lacking regarding trials against other treatments currently used in ALS. Furthermore, the existing evidence provides limited insight into whether the medicine can play a role in individuals who have not yet received a definite ALS diagnosis but may be experiencing early, subtle symptoms.

Key Studies & References

  1. Amyotrophic lateral sclerosis (ALS) (motor neuron disease): assessment and management (NICE Guideline NG42)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Riluzol-Hormosan (FAQ)

Q: Is Riluzol-Hormosan a cure for the condition it is prescribed for?

Official regulatory documents state that Riluzole is used to extend life or delay the need for mechanical ventilation in patients with ALS. The medicine is designed to provide a neuroprotective effect by slowing down certain processes, but it is not described as a cure for the underlying disease.

Q: Are the tablet, suspension, and oral film versions of riluzole considered interchangeable?

The different formulations—tablet, oral suspension, and oral film—are different product types that contain the same active substance (Riluzole). These forms were developed primarily to help patients who may have difficulty swallowing tablets. Decisions regarding changing formulations should be reviewed with a prescribing physician.

Q: Is Riluzol-Hormosan the same as other brands like Rilutek or Tiglutik?

Riluzol-Hormosan is a specific trade name that contains the active substance Riluzole. This is the same essential chemical compound found in other authorized brand names, such as Rilutek, Tiglutik, and Exservan.

Q: What are the signs of a potential liver problem that require attention from a healthcare provider?

The monitoring of patients for signs of liver injury is addressed in official product information. These signs can include unexplained nausea, vomiting, abdominal pain, loss of appetite, fatigue, yellowing of the skin or eyes (jaundice), and dark urine. Official guidance describes the prompt reporting of these signs as part of the safety protocol.

Q: Why do some users report a numbness or tingling feeling around the mouth?

The feeling of numbness or decreased sensation in the mouth is described in regulatory documents as oral hypoesthesia. This is listed as a common adverse reaction associated with Riluzole formulations found during clinical trials.

Q: Is the effectiveness of Riluzol-Hormosan affected by smoking or nicotine use?

Official documents indicate that smoking or tobacco use may cause an interaction with Riluzole because nicotine can affect the liver enzyme CYP1A2, which is responsible for breaking down the medicine. Regulatory guidance highlights the importance of patients informing their healthcare provider about their tobacco use.

Q: Can taking Riluzol-Hormosan with alcohol consumption cause issues?

Riluzole is known to interact with alcohol. Using this medicine alongside alcohol consumption can potentially increase the risk of certain side effects, such as dizziness or feeling faint.

Q: Why is Riluzol-Hormosan required to be taken on an empty stomach?

The official administration instructions require the medicine to be taken on an empty stomach—at least one hour before or two hours after a meal—to ensure proper absorption. Taking Riluzole with food significantly reduces the amount of medicine absorbed into the body, which is linked to decreased drug exposure.

Q: Why do official sources mention using Riluzol-Hormosan with caution in older adults?

While official documents note that the same dose is used and the adverse reaction profile was similar in older and younger patients, general caution is advised. This is primarily because common side effects like dizziness and weakness may have a greater impact on the ability of older adults to perform skilled or daily tasks.

Q: Can Riluzol-Hormosan be prescribed to people with motor neuron diseases other than ALS?

No. According to official regulatory documents, Riluzole is indicated only for patients with a definite diagnosis of Amyotrophic Lateral Sclerosis (ALS). Use in patients with any other form of motor-neurone disease is generally not recommended in official European regulatory documents.

Q: Can Riluzol-Hormosan cause an increase in blood pressure?

Yes. Official product information lists Hypertension (increased blood pressure) as one of the common adverse reactions reported in Riluzole-treated patients during clinical trials.

Q: What are the signs of an allergic reaction to the drug?

Serious signs of an allergic reaction or severe hypersensitivity, which are listed as a contraindication, can include hives, rash, itching, and difficulty breathing or swallowing. Official guidance indicates that immediate medical attention is necessary if these signs are experienced.

Q: Are stomach pain and diarrhea common side effects of the medication?

Yes, both abdominal pain (stomach pain) and diarrhea are listed among the common adverse reactions reported in clinical trials for Riluzole formulations. These effects involve the gastrointestinal system and are listed in the official safety profile.

Q: Does Riluzol-Hormosan have to be taken exactly 12 hours apart to be effective?

Official regulatory instructions indicate that the two daily doses are administered approximately 12 hours apart. The use of the word 'approximately' suggests that maintaining the interval within a reasonable range is the focus, rather than requiring an exact 12-hour gap.

Q: What is the official safety classification of Riluzol-Hormosan?

Riluzole is assigned as Pregnancy Category C by the FDA, which indicates that risk to the fetus cannot be ruled out. Furthermore, official documents state that the use of Riluzole is contraindicated during both pregnancy and breastfeeding.

Q: Is the onset of potential side effects typically immediate or delayed after starting Riluzol-Hormosan?

The onset of adverse effects is variable. Official safety information specifically notes that maximum increases in liver enzymes are most frequently observed to occur within the first three months of treatment. Cases of severe neutropenia (low white blood cell count) have been reported within the first two months.

Q: Are there any known restrictions related to using Riluzol-Hormosan for individuals who have not yet received a definite diagnosis?

Official regulatory documents state that Riluzole is indicated only for patients with a definite diagnosis of ALS. Use is generally restricted to patients who have a confirmed diagnosis, as specified in the product's official labeling.

Q: What is the specific chemical classification of Riluzol-Hormosan (e.g. benzothiazole derivative)?

The active substance in this medicine, Riluzole, is chemically classified by the U.S. National Library of Medicine as a member of the benzothiazole derivative group. This classification defines its core chemical structure.

Q: What are the long-term outcomes and limitations of data collection for Riluzol-Hormosan?

The initial clinical trials that established the medicine's efficacy had limited follow-up periods, typically up to 18 months. While benefits like survival time prolongation were observed, the regulatory reviews noted that the medicine was not more effective than placebo in the late stages of ALS, highlighting the limitations of the long-term data available.

Advertisements

How should Riluzol-Hormosan be stored and disposed of?

How to Store and Dispose of Riluzol-Hormosan?

The storage and disposal instructions for Riluzole are defined by official regulatory documentation and differ between the tablet and oral suspension formulations.


Storage Conditions

Formulation Required Storage Condition
Oral Tablets (Riluzol-Hormosan) Do not require any special storage conditions.
Oral Suspension Store at controlled room temperature (20 C to 25 C) and protect from bright light. Do not freeze.

Key Stability and Safety Rules

Both formulations must be kept out of the sight and reach of children. The oral suspension, once opened, must be used within 15 days, after which any remaining portion must be discarded. Disposal of any unused or expired product must be in accordance with local requirements and should not be discarded via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Riluzol-Hormosan found in:

A-Z Index: